Contrasting MPX International (OTCMKTS:MPXOF) & Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) and MPX International (OTCMKTS:MPXOF) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

80.0% of Heron Therapeutics shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Heron Therapeutics and MPX International”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$151.18 million	0.43	-$20.19 million	($0.19)	-1.79
MPX International	N/A	N/A	N/A	N/A	N/A

MPX International has lower revenue, but higher earnings than Heron Therapeutics.

Profitability

This table compares Heron Therapeutics and MPX International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-265.11%	-10.02%
MPX International	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Heron Therapeutics and MPX International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1	3	1	0	2.00
MPX International	0	0	0	0	0.00

Heron Therapeutics currently has a consensus price target of $2.00, indicating a potential upside of 486.68%. Given Heron Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Heron Therapeutics is more favorable than MPX International.

Summary

Heron Therapeutics beats MPX International on 6 of the 9 factors compared between the two stocks.

About Heron Therapeutics

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

About MPX International

MPX International Corporation, operates as a cannabis company in Canada and internationally. It offers cannabis products under HOLYWEED, beleaf, SALSUS, MPX labs, Canveda, SPARTAN WELLNESS, HIGH12, STRAIN REE, PENNIES, Kingsway, DAIZE, and alice brands. The company was founded in 2015 and is headquartered in Toronto, Canada.